Atrys HealthXMAD:ATRY +0.19%68 Days Payable is 110.14 as of Dec. 2025, which is 30% below its 10-year median of 157.31. GuruFocus rates XMAD:ATRY with a GF Score™ of 68/100 and a GF Value™ of €3.11 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 707 Biotechnology companies, Atrys Health ranks worse than 51.63% on this metric.
The historical rank and industry rank for Atrys Health's Days Payable or its related term are showing as below:
XMAD:ATRY'
s Days Payable Range Over the Past 10 Years
Min: 98.8 Med: 157.31 Max: 2507.11
Current: 105.1
During the past 10 years, Atrys Health's highest Days Payable was 2507.11. The lowest was 98.80. And the median was 157.31.
XMAD:ATRY's Days Payable is ranked worse than 51.63% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs XMAD:ATRY: 105.10
Atrys Health's Days Payable
declined
from Dec. 2024 (114.52) to Dec. 2025 (110.14).
It may suggest that Atrys Healthaccelerated paying its suppliers.
Atrys Health Days Payable Related Terms
Atrys Health Days Payable Historical Data
* Premium members only.
The historical data trend for Atrys Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ATRY vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Atrys Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrys Health Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrys Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Atrys Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Atrys Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atrys Health (XMAD:ATRY) has a Days Payable of 110.14 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Atrys Health and its competitors. This is 30% below median its historical median of 157.31. Over the past decade, Atrys Health's Days Payable has ranged from 98.80 to 2,507.11. According to the industry distribution chart, Atrys Health ranks #365 out of 707 companies in the Biotechnology industry, placing it in the top 51.6%.
Is Atrys Health's Days Payable too high?
Atrys Health's current Days Payable of 110.14 is 30% below median its 10-year median of 157.31. Over the past 10 years, this metric has ranged from a low of 98.80 to a high of 2,507.11. The Biotechnology industry median Days Payable is 113.76. Atrys Health's value of 110.14 is 3.2% below this industry median. Based on the distribution chart, Atrys Health ranks #365 out of 707 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atrys Health has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #365 out of 707 companies for Days Payable. This places Atrys Health in the lower half of its industry. The industry median Days Payable is 113.76. Atrys Health's value of 110.14 is 3.2% below this benchmark. Historically, Atrys Health's own Days Payable has ranged from 98.80 to 2,507.11 over the past decade. While the company's 10-year median is 157.31 vs. the industry median of 113.76, Atrys Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atrys Health's current Days Payable of 110.14 is 3.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Atrys Health and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrys Health's current Days Payable is 110.14, which is 30% below median its own 10-year median of 157.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.11, compared to a current price of €2.58 — trading 17% below its estimated fair value. The current Days Payable is 110.14, which is 30% below median its 10-year median of 157.31 and 3.2% below the Biotechnology industry median of 113.76. Atrys Health's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Days Payable is 110.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atrys Health (XMAD:ATRY) Overvalued in 2026?
Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued.
The current stock price of €2.58 is trading 17% below its estimated GF Value™ of €3.11.
GuruFocus considers Atrys Health to be Modestly Undervalued.
Key valuation signals for XMAD:ATRY:
Days Payable: 110.14 (30% below median its 10-year median of 157.31)
GF Value™: €3.11 vs. price of €2.58 (17% below fair value)
Industry Position: 3.2% below the Biotechnology median (#365 of 707)
No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
68GF Score
Get the complete analysis for XMAD:ATRY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ATRY has been successfully added to your 
